Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

Contributed by: Business Wire

Logo

Tags

Health

Neurology

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Alzheimer's

More Like This

Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON

ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption

ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies

ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape

ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer

ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research

ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study